MeAgain is stronger if you want a GLP-1 tracker that feels more supportive, more human, and easier to come back to
In 2025, the company reported a +4.31% YoY revenue growth, driven by its specialty segment momentum: Austedo ($2.21B) continues to be the key growth driver with strong uptake in movement disorders, Copaxone ($255M) continues its decline due to generic competition, while UZEDY ($191M) is gaining early traction as a long-acting injectable for schizophrenia, reflecting Tevas push into differentiated CNS therapies
Did you just start the medication
May your follicles stay active, your nutrients stay abundant, and your recovery stay steady.
Dulaglutide sales surged starting in 2019 and became the top seller in GLP-1RA in 2020
Santos, a doctor the recipient does not know